ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Memory Pharmaceuticals & Roche Expand Development Program For MEM 3454 In Schizophrenia
Memory
Pharmaceuticals Corp. (Nasdaq: MEMY) announced that it plans to
conduct a clinical study of MEM 3454, the Company's lead nicotinic alpha-7
partial agonist, on two biomarkers of schizophrenia, P50 sensory gating and
mismatch negativity, in patients with schizophrenia. The biomarker study,
and additional formulation and manufacturing activities for MEM 3454, will
be funded by Roche, under the companies' collaboration for the development
of nicotinic alpha-7 receptor agonists.
"This new study will greatly enhance our ability to measure and predict
the efficacy of MEM 3454 and other compounds in the nicotinic alpha-7
receptor program," said Stephen Murray, MD, Ph.D, Chief Medical Officer of
Memory Pharmaceuticals Corp. "The study should be underway this summer with
data available by early 2009. The biomarker data, together with the results
of our ongoing Phase 2a study in CIAS, will help with the design of
later-stage trials in schizophrenia."
The biomarker study will enroll approximately 12 patients with stable
schizophrenia who are receiving atypical antipsychotic therapy. Subjects
will be randomized to receive MEM 3454 and placebo in a 5-way cross-over
design. Each subject will participate in 5 treatment periods. During each
period, subjects will receive single doses of 1 mg, 5 mg, 15 mg, or 50 mg
of MEM 3454 or placebo, with a 4-day wash-out period between each treatment
period. The primary objective of the trial is to study P50 sensory gating
and mismatch negativity as potential efficacy biomarkers for nicotinic
alpha-7 agonists, such as MEM 3454, in schizophrenia. P50 sensory gating
and mismatch negativity are two neurophysiological measurements that have
been shown to be closely associated with nicotinic alpha-7 function and
schizophrenia.
In November 2007, Memory Pharmaceuticals announced positive Phase 2a
data from a clinical trial of MEM 3454 in Alzheimer's disease. MEM 3454
demonstrated a statistically significant effect on cognition at the 5 mg
and 15 mg doses on both the primary and key secondary endpoints for that
trial. Roche has an option to a worldwide, exclusive license to develop and
commercialize MEM 3454 upon the delivery by Memory of the study report of
the Phase 2a AD study and the fulfillment of certain additional predefined
events. Roche is obligated to make a milestone payment to Memory
Pharmaceuticals at the time this option is exercised.
In December 2007, as part of the development program for MEM 3454 in
schizophrenia, Memory Pharmaceuticals commenced a Phase 2a clinical trial
of MEM 3454 in CIAS. To maintain its license to MEM 3454, Roche would have
to make an additional milestone payment to the Company upon completion of
the ongoing Phase 2a CIAS trial, which is expected to be completed in the
fourth quarter of 2008.
Evoked Potentials in Schizophrenia
Electrophysiology measures have long been used to detect changes in
brain activity in patients with schizophrenia. These patients often have a
diminished ability to suppress the evoked response to the second of two
auditory stimuli, which is known as sensory gating. A number of both
preclinical and clinical studies have shown that this abnormality is
genetically linked to the nicotinic alpha-7 receptor and can be measured
through the P50 auditory evoked response, a positive waveform measured 50
milliseconds after an auditory stimulus. Recent scientific studies have
shown that a nicotinic alpha-7 agonist can both improve cognition and
improve P50 inhibition, giving rise to the possibility that P50 can be used
to track cognitive effects for this class of compounds. Another auditory
electrophysiology evoked potential measure that is abnormal in patients
with schizophrenia is mismatched negativity, which is the ability to detect
a deviation from a repetitive auditory pattern. Both of these evoked
potential abnormalities in schizophrenia have been shown to be reversed by
treatment.
About MEM 3454
MEM 3454 is a partial agonist of the nicotinic alpha-7 receptor, a
highly specialized receptor found in the central nervous system. Compounds
acting on this receptor could be beneficial in the treatment of Alzheimer's
disease and schizophrenia, as well as other psychiatric and neurological
disorders. MEM 3454 is being developed by Memory Pharmaceuticals under its
Strategic Alliance Agreement with Roche for the development of nicotinic
alpha-7 receptor agonists and is the Company's lead drug candidate from its
nicotinic alpha-7 agonist program.
About the Company
Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused
on developing innovative drugs for the treatment of debilitating CNS
disorders such as Alzheimer's disease, schizophrenia and depression. For
additional information, please visit our website at
http://www.memorypharma.com.
Safe Harbor Statement
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks and uncertainties. All statements, other than statements
of historical facts, regarding management's expectations, beliefs, goals,
plans or Memory Pharmaceuticals' prospects, future financial position,
future revenues and projected costs should be considered forward-looking.
Readers are cautioned that actual results may differ materially from
projections or estimates due to a variety of important factors, including
the risks and uncertainties associated with: obtaining additional financing
to support Memory Pharmaceuticals' R&D and clinical activities and
operations; the outcome of clinical trials of Memory Pharmaceuticals' drug
candidates and whether they demonstrate these candidates' safety and
effectiveness; obtaining regulatory approvals to conduct clinical trials
and to commercialize Memory Pharmaceuticals' drug candidates; Memory
Pharmaceuticals' ability to enter into and maintain collaborations with
third parties for its drug development programs; Memory Pharmaceuticals'
dependence on its collaborations and its license relationships; achieving
milestones under Memory Pharmaceuticals' collaborations; Memory
Pharmaceuticals' dependence on preclinical and clinical investigators,
preclinical and clinical research organizations, manufacturers and
consultants; and protecting the intellectual property developed by or
licensed to Memory Pharmaceuticals. These and other risks are described in
greater detail in Memory Pharmaceuticals' filings with the Securities and
Exchange Commission. Memory Pharmaceuticals may not actually achieve the
goals or plans described in its forward-looking statements, and investors
should not place undue reliance on these statements. Memory Pharmaceuticals
disclaims any intent or obligation to update any forward-looking statements
as a result of developments occurring after the date of this press release.
Memory Pharmaceuticals Corp.
http://www.memorypharma.com
Memorie de produse farmaceutice Roche & expandare program de dezvoltare pentru 3454 mem în schizofrenie - Memory Pharmaceuticals & Roche Expand Development Program For MEM 3454 In Schizophrenia - articole medicale engleza - startsanatate